Trial Profile
A Prospective, Multicenter, Randomized, Open-Label, Controlled Study Evaluating Safety and Preliminary Efficacy of NeoFuse When Combined With MasterGraft Matrix in Subjects Undergoing Lumbar Interbody Fusion With Instrumentation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Dec 2016
Price :
$35
*
At a glance
- Drugs Rexlemestrocel-L (Primary)
- Indications Intervertebral disc degeneration; Spinal stenosis
- Focus Adverse reactions
- Sponsors Mesoblast
- 15 Dec 2016 Status changed from active, no longer recruiting to completed.
- 21 Nov 2014 New trial record